OZEMPIC (Novo Nordisk Pharmaceuticals Pty Ltd)
Product name
OZEMPIC
Date registered
Evaluation commenced
Decision date
Approval time
177 working days (255)
Active ingredients
semaglutide (rys)
Registration type
NCE/NBE
Indication
OZEMPIC (solution for injection) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
- as monotherapy when metformin is not tolerated or contraindicated.
- in addition to other medicinal products for the treatment of type 2 diabetes.